- Home
- JHS vs ENTA Comparison
JHS vs ENTA Comparison
Compare JHS & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- ENTA
- Stock Information
- Founded
- JHS 1973
- ENTA 1995
- Country
- JHS United States
- ENTA United States
- Employees
- JHS N/A
- ENTA N/A
- Industry
- JHS Finance Companies
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- JHS Finance
- ENTA Health Care
- Exchange
- JHS Nasdaq
- ENTA Nasdaq
- Market Cap
- JHS 135.2M
- ENTA 127.8M
- IPO Year
- JHS N/A
- ENTA 2013
- Fundamental
- Price
- JHS $11.34
- ENTA $5.94
- Analyst Decision
- JHS
- ENTA Buy
- Analyst Count
- JHS 0
- ENTA 4
- Target Price
- JHS N/A
- ENTA $19.50
- AVG Volume (30 Days)
- JHS 32.8K
- ENTA 464.3K
- Earning Date
- JHS 01-01-0001
- ENTA 02-05-2025
- Dividend Yield
- JHS 3.96%
- ENTA N/A
- EPS Growth
- JHS N/A
- ENTA N/A
- EPS
- JHS 0.02
- ENTA N/A
- Revenue
- JHS N/A
- ENTA $67,635,000.00
- Revenue This Year
- JHS N/A
- ENTA $11.80
- Revenue Next Year
- JHS N/A
- ENTA $3.99
- P/E Ratio
- JHS $553.50
- ENTA N/A
- Revenue Growth
- JHS N/A
- ENTA N/A
- 52 Week Low
- JHS $9.76
- ENTA $5.84
- 52 Week High
- JHS $11.25
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- JHS 35.76
- ENTA 24.81
- Support Level
- JHS $11.36
- ENTA $5.84
- Resistance Level
- JHS $11.47
- ENTA $6.56
- Average True Range (ATR)
- JHS 0.08
- ENTA 0.73
- MACD
- JHS -0.03
- ENTA -0.18
- Stochastic Oscillator
- JHS 0.00
- ENTA 2.67
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash & commercial paper.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.